Institutional investors hold a majority ownership of BIIB through the 93.07% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended September 2014, these large investors purchased a net $196.2 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 596.4 Thousand shares of Biogen
WINSLOW CAPITAL MANAGEMENT LLC Bought 448.2 Thousand shares of Biogen